{"entity":{"type":"insider","cik":"0001723787","url":"/insider/0001723787","json_url":"/insider/0001723787.json","name":"Bratton Capital Management, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":5,"first":"2017-12-14","last":"2020-12-15","span_basis":"filed_date"},"name_variants":[{"name":"Bratton Capital Management, L.P.","source":"filing","n_filings":5,"first_seen":"2017-12-14","last_seen":"2020-12-15"}],"transactions":[{"id":2513820,"accession":"0000899243-20-033903","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-033903","line_url":"/filing/0000899243-20-033903","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Inc.; Bratton Capital Management, L.P.; Neuro Line Partners LP; BRATTON DOUGLAS K","owner_display_name":"Bratton Capital Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17825.0,"shares_display":"17,825","price_per_share":80.38386536886395,"price_display":"80.38","price_state":"stated","total_value":1432842.4002,"total_display":"1,432,842.40","total_whole":"1,432,842","shares_owned_after":384287.0,"shares_owned_after_display":"384,287","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-14","filed_date":"2020-12-15","scope":"insider","n_lines":2},{"id":2513807,"accession":"0000899243-20-033903","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-033903","line_url":"/filing/0000899243-20-033903#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Inc.; Bratton Capital Management, L.P.; Neuro Line Partners LP; BRATTON DOUGLAS K","owner_display_name":"Bratton Capital Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46799.0,"shares_display":"46,799","price_per_share":80.0539,"price_display":"80.05","price_state":"stated","total_value":3746442.4661,"total_display":"3,746,442.47","total_whole":"3,746,442","shares_owned_after":401236.0,"shares_owned_after_display":"401,236","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-11","filed_date":"2020-12-15","scope":"insider"},{"id":3309893,"accession":"0000899243-20-018024","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-018024","line_url":"/filing/0000899243-20-018024","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Management, L.P.; Bratton Capital Inc.; Neuro Line Partners LP; BRATTON DOUGLAS K","owner_display_name":"Bratton Capital Management, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":45345.0,"shares_display":"45,345","price_per_share":24.007074914544052,"price_display":"24.01","price_state":"stated","total_value":1088600.812,"total_display":"1,088,600.81","total_whole":"1,088,601","shares_owned_after":448235.0,"shares_owned_after_display":"448,235","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-30","filed_date":"2020-06-30","scope":"insider","n_lines":2},{"id":3309882,"accession":"0000899243-20-018024","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-018024","line_url":"/filing/0000899243-20-018024","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Management, L.P.; Bratton Capital Inc.; Neuro Line Partners LP; BRATTON DOUGLAS K","owner_display_name":"Bratton Capital Management, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":82578.0,"shares_display":"82,578","price_per_share":24.006069316282787,"price_display":"24.01","price_state":"stated","total_value":1982373.192,"total_display":"1,982,373.19","total_whole":"1,982,373","shares_owned_after":514151.0,"shares_owned_after_display":"514,151","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-29","filed_date":"2020-06-30","scope":"insider","n_lines":2},{"id":3309875,"accession":"0000899243-20-018024","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-018024","line_url":"/filing/0000899243-20-018024","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Management, L.P.; Bratton Capital Inc.; Neuro Line Partners LP; BRATTON DOUGLAS K","owner_display_name":"Bratton Capital Management, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":122077.0,"shares_display":"122,077","price_per_share":23.93634826298156,"price_display":"23.94","price_state":"stated","total_value":2922077.5869,"total_display":"2,922,077.59","total_whole":"2,922,078","shares_owned_after":589562.0,"shares_owned_after_display":"589,562","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-26","filed_date":"2020-06-30","scope":"insider","n_lines":2},{"id":2287591,"accession":"0000899243-20-017498","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-017498","line_url":"/filing/0000899243-20-017498","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Management, L.P.; Bratton Capital Inc.; BRATTON DOUGLAS K; Neuro Line Partners LP","owner_display_name":"Bratton Capital Management, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20024.0,"shares_display":"20,024","price_per_share":25.7675101378346,"price_display":"25.77","price_state":"stated","total_value":515968.623,"total_display":"515,968.62","total_whole":"515,969","shares_owned_after":701282.0,"shares_owned_after_display":"701,282","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-23","filed_date":"2020-06-23","scope":"insider","n_lines":2},{"id":2287580,"accession":"0000899243-20-017498","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-017498","line_url":"/filing/0000899243-20-017498","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Management, L.P.; Bratton Capital Inc.; BRATTON DOUGLAS K; Neuro Line Partners LP","owner_display_name":"Bratton Capital Management, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":90056.0,"shares_display":"90,056","price_per_share":24.783487246824198,"price_display":"24.78","price_state":"stated","total_value":2231901.7275,"total_display":"2,231,901.73","total_whole":"2,231,902","shares_owned_after":742742.0,"shares_owned_after_display":"742,742","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-22","filed_date":"2020-06-23","scope":"insider","n_lines":2},{"id":2287570,"accession":"0000899243-20-017498","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-017498","line_url":"/filing/0000899243-20-017498","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Bratton Capital Management, L.P.; Bratton Capital Inc.; BRATTON DOUGLAS K; Neuro Line Partners LP","owner_display_name":"Bratton Capital Management, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":144920.0,"shares_display":"144,920","price_per_share":24.54114450248413,"price_display":"24.54","price_state":"stated","total_value":3556502.6613,"total_display":"3,556,502.66","total_whole":"3,556,503","shares_owned_after":870554.0,"shares_owned_after_display":"870,554","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-19","filed_date":"2020-06-23","scope":"insider","n_lines":2},{"id":5952023,"accession":"0000897423-18-000055","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000897423-18-000055","line_url":"/filing/0000897423-18-000055#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Aquestive Therapeutics, Inc.","issuer_ticker":"AQST","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"BRATTON DOUGLAS K; Bratton Capital Inc.; Monoline Partners, L.P.; Bratton Capital Management, L.P.","owner_display_name":"BRATTON DOUGLAS K","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":165000.0,"shares_display":"165,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2475000.0,"total_display":"2,475,000.00","total_whole":"2,475,000","shares_owned_after":165000.0,"shares_owned_after_display":"165,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-24","filed_date":"2018-07-26","scope":"insider"},{"id":4257138,"accession":"0000899243-17-028694","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-17-028694","line_url":"/filing/0000899243-17-028694#line-7","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Crestline Management, LP; Bratton Capital Inc.; Crestline Investors, Inc.; Bratton Capital Management, L.P.; BRATTON DOUGLAS K; AKDL, L.P.; Neuro Line Partners LP; Crestline SI (GP), L.P.","owner_display_name":"Crestline Management, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":275000.0,"shares_display":"275,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":4950000.0,"total_display":"4,950,000.00","total_whole":"4,950,000","shares_owned_after":19462499.0,"shares_owned_after_display":"19,462,499","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-12","filed_date":"2017-12-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001714899","name":"Denali Therapeutics Inc.","url":"/issuer/0001714899","role":"Ten percent owner","n_filings":4,"first_seen":"2017-12-14","last_seen":"2020-12-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001398733","name":"Aquestive Therapeutics, Inc.","url":"/issuer/0001398733","role":"Ten percent owner","n_filings":1,"first_seen":"2018-07-26","last_seen":"2018-07-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001723787","retrieved_at":"2026-08-25T17:56:45+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}